(CGEN) Compugen - Overview
Stock: Anti-PVRIG, Anti-TIGIT, Anti-ILDR2, Bispecific Antibody, IL-18 Blocker
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.8% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -54.21 |
| Character TTM | |
|---|---|
| Beta | 1.307 |
| Beta Downside | 1.096 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.59% |
| CAGR/Max DD | 0.44 |
Description: CGEN Compugen January 10, 2026
Compugen Ltd. (NASDAQ:CGEN) is a clinical-stage therapeutic discovery firm headquartered in Holon, Israel, with R&D activities across Israel, the United States, and Europe. The company focuses on immuno-oncology antibodies and bispecifics, positioning itself in the GICS sub-industry “Life Sciences Tools & Services.”
Its current clinical portfolio includes:
- COM701 – an anti-PVRIG antibody evaluated in Phase 1 as monotherapy and in combination with PD-1 or TIGIT blockade.
- COM902 – an anti-TIGIT antibody also in Phase 1, explored in similar combination regimens.
- Bapotulimab – an ILDR2-targeting antibody in Phase 1 for treatment-naïve head-and-neck squamous cell carcinoma.
- Rilvegostomig – a bispecific anti-TIGIT/PD-1 antibody currently in a Phase III trial for advanced/metastatic non-small cell lung cancer.
Pre-clinical assets such as COM503 (an IL-18 pathway blocker) expand the pipeline’s breadth against immune resistance mechanisms.
Compugen leverages strategic partnerships to de-risk development and accelerate commercialization: a clinical collaboration with Bristol-Myers Squibb (BMS) to test COM701 alongside Opdivo, a licensing deal with AstraZeneca for bispecific and multispecific antibody platforms, and a research-development-manufacturing agreement with Gilead Sciences covering COM503 and future candidates.
From a market-side perspective, the global immuno-oncology sector is projected to grow at a ~10 % CAGR through 2028, driven by expanding indications for checkpoint inhibitors and increasing payer acceptance of combination regimens. As of the latest 10-K, Compugen reported a cash runway of roughly $150 million and FY 2023 R&D spend of $45 million, giving it ~3-year liquidity assuming current burn rates. The company’s valuation hinges on the probability-adjusted success of its late-stage bispecific (Rilvegostomig) and the ability to monetize partnerships, both of which remain highly uncertain and sensitive to trial outcomes.
For a deeper quantitative assessment of CGEN’s valuation metrics, the ValueRay platform offers a concise dashboard of forward-looking cash-flow and risk-adjusted returns.
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income: -27.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.51 > 0.02 and ΔFCF/TA 79.77 > 1.0 |
| NWC/Revenue: 994.3% < 20% (prev 145.5%; Δ 848.8% < -1%) |
| CFO/TA 0.51 > 3% & CFO 49.6m > Net Income -27.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (93.5m) vs 12m ago 4.14% < -2% |
| Gross Margin: 7.43% > 18% (prev 0.85%; Δ 658.6% > 0.5%) |
| Asset Turnover: 6.24% > 50% (prev 48.46%; Δ -42.22% > 0%) |
| Interest Coverage Ratio: -947.1 > 6 (EBITDA TTM -30.2m / Interest Expense TTM 34.0k) |
Altman Z'' -15.00
| A: 0.70 (Total Current Assets 88.9m - Total Current Liabilities 20.3m) / Total Assets 97.8m |
| B: -5.00 (Retained Earnings -488.8m / Total Assets 97.8m) |
| C: -0.29 (EBIT TTM -32.2m / Avg Total Assets 110.7m) |
| D: -9.04 (Book Value of Equity -488.5m / Total Liabilities 54.0m) |
| Altman-Z'' Score: -23.13 = D |
Beneish M 1.00
| DSRI: 11.57 (Receivables 2.83m/2.12m, Revenue 6.90m/59.9m) |
| GMI: 11.37 (GM 7.43% / 84.53%) |
| AQI: 1.46 (AQ_t 0.06 / AQ_t-1 0.04) |
| SGI: 0.12 (Revenue 6.90m / 59.9m) |
| TATA: -0.79 (NI -27.6m - CFO 49.6m) / TA 97.8m) |
| Beneish M-Score: 13.90 (Cap -4..+1) = D |
What is the price of CGEN shares?
Over the past week, the price has changed by -9.24%, over one month by +7.74%, over three months by +1.83% and over the past year by -33.73%.
Is CGEN a buy, sell or hold?
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CGEN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | 247.3% |
| Analysts Target Price | 5.8 | 247.3% |
| ValueRay Target Price | 1.5 | -10.2% |
CGEN Fundamental Data Overview February 02, 2026
P/B = 4.1191
Revenue TTM = 6.90m USD
EBIT TTM = -32.2m USD
EBITDA TTM = -30.2m USD
Long Term Debt = 2.95m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 486.0k USD (from shortTermDebt, last quarter)
Debt = 2.95m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.51m USD (from netDebt column, last quarter)
Enterprise Value = 90.1m USD (173.2m + Debt 2.95m - CCE 86.1m)
Interest Coverage Ratio = -947.1 (Ebit TTM -32.2m / Interest Expense TTM 34.0k)
EV/FCF = 1.82x (Enterprise Value 90.1m / FCF TTM 49.5m)
FCF Yield = 54.95% (FCF TTM 49.5m / Enterprise Value 90.1m)
FCF Margin = 716.9% (FCF TTM 49.5m / Revenue TTM 6.90m)
Net Margin = -400.1% (Net Income TTM -27.6m / Revenue TTM 6.90m)
Gross Margin = 7.43% ((Revenue TTM 6.90m - Cost of Revenue TTM 6.39m) / Revenue TTM)
Gross Margin QoQ = 12.74% (prev -32.46%)
Tobins Q-Ratio = 0.92 (Enterprise Value 90.1m / Total Assets 97.8m)
Interest Expense / Debt = 1.15% (Interest Expense 34.0k / Debt 2.95m)
Taxrate = 21.0% (US default 21%)
NOPAT = -25.4m (EBIT -32.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.38 (Total Current Assets 88.9m / Total Current Liabilities 20.3m)
Debt / Equity = 0.07 (Debt 2.95m / totalStockholderEquity, last quarter 43.8m)
Debt / EBITDA = 0.15 (negative EBITDA) (Net Debt -4.51m / EBITDA -30.2m)
Debt / FCF = -0.09 (Net Debt -4.51m / FCF TTM 49.5m)
Total Stockholder Equity = 51.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.95% (Net Income -27.6m / Total Assets 97.8m)
RoE = -53.60% (Net Income TTM -27.6m / Total Stockholder Equity 51.5m)
RoCE = -59.11% (EBIT -32.2m / Capital Employed (Equity 51.5m + L.T.Debt 2.95m))
RoIC = -46.32% (negative operating profit) (NOPAT -25.4m / Invested Capital 54.9m)
WACC = 10.57% (E(173.2m)/V(176.2m) * Re(10.73%) + D(2.95m)/V(176.2m) * Rd(1.15%) * (1-Tc(0.21)))
Discount Rate = 10.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 2.86%
[DCF Debug] Terminal Value 73.39% ; FCFF base≈49.5m ; Y1≈61.0m ; Y5≈104.0m
Fair Price DCF = 12.35 (EV 1.15b - Net Debt -4.51m = Equity 1.16b / Shares 93.5m; r=10.57% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.10 | EPS CAGR: 43.70% | SUE: 1.38 | # QB: 1
Revenue Correlation: 53.70 | Revenue CAGR: 172.5% | SUE: 0.06 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-0.33 | Chg30d=-0.012 | Revisions Net=+1 | Growth EPS=-308.3% | Growth Revenue=-9.1%